Latest filingSep 01, 2026Most recent Form 4
FENC
FENNEC PHARMACEUTICALS INC.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$102M2 sells
Net open-market-$102M5 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period9transactions
- A · Grants / awards · dominant5 · 56%
- M · Option exercise2 · 22%
- S · Open-market sells2 · 22%
Activity by reported role
A joint filing can contribute to multiple roles9transactions
- Chief financial officer · dominant4 · 44%
- CMO2 · 22%
- CCO1 · 11%
- Chief executive officer1 · 11%
- CSO1 · 11%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (5)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeAndrade RobertCommon shares · Direct
241,306Aug 31, 2026
Sayad Pierre SargisCommon Shares · Direct
21,519Aug 31, 2026
Andrade RobertStock Options · Direct
779,330Aug 28, 2026
Hackman Jeffrey S.Common Shares · Direct
66,302Aug 31, 2026
Cioffi Christiana MarieCommon shares · Direct
24,644Aug 31, 2026
Evans Terry LCommon Shares · Direct
21,519Aug 31, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- SS-$146.2k
- EL+$0
- CM+$0
- HS+$0
- AR+$0
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
FENC transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| FENC | Sayad Pierre Sargis | CMO | sale | 12.0k | -$14.6M | S | 0.0% | 09/01 | 08/31 | |
| FENC | Sayad Pierre Sargis | CMO | grant | 168 | $0 | A | 0.0% | 09/01 | 08/31 | |
| FENC | Evans Terry L | CCO | grant | 168 | $0 | A | 0.0% | 09/01 | 08/31 | |
| FENC | Cioffi Christiana Marie | CSO | grant | 156 | $0 | A | 0.0% | 09/01 | 08/31 | |
| FENC | Hackman Jeffrey S. | CEO | grant | 1.15k | $0 | A | 0.0% | 09/01 | 08/31 | |
| FENC | Andrade Robert | CFO | grant | 1.70k | $0 | A | 0.0% | 09/01 | 08/31 |
FENNEC PHARMACEUTICALS INC. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at FENNEC PHARMACEUTICALS INC.?
Sayad Pierre Sargis, Evans Terry L, Cioffi Christiana Marie, Hackman Jeffrey S., Andrade Robert.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Sayad Pierre Sargis reported a sale on Aug 31, 2026 valued at $14.6M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,029,660.00. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.